Regulatory Alerts, Diabetes and other endocrinal, nutritional and metabolic conditions, Diabetes, Diabetes Room
Drug Safety Update: dapagliflozin (Forxiga) no longer authorised for treatment of type 1 diabetes mellitus
The authorisation holder for dapagliflozin has withdrawn the indication for type 1 diabetes mellitus. The removal of the type 1 diabetes indication is not due to any new safety concerns and the other indications of dapagliflozin are unchanged.
